Phase 1 Expansion Study of XMT-1536, a Novel NaPi2b-targeting Antibody-Drug Conjugate (ADC): Preliminary Efficacy, Safety, and Biomarker Results in Patients with Previously Treated Metastatic Ovarian Cancer (OC) or Non-Small Cell Lung Cancer (NSCLC)